MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

78.34
+1.91
+2.50%
After Hours: 78.34 0 0.00% 17:05 09/16 EDT
OPEN
76.19
PREV CLOSE
76.43
HIGH
79.04
LOW
75.60
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
89.30
52 WEEK LOW
57.00
MARKET CAP
16.85B
P/E (TTM)
55.54
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INCY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

INCY News

  • BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
  • GlobeNewswire.9h ago
  • Novartis Presses Forward With Plan To Get New Treatment Options For Subset Of NSCLC Population
  • Seeking Alpha - Article.3d ago
  • Is There An Opportunity With Incyte Corporation's (NASDAQ:INCY) 29% Undervaluation?
  • Simply Wall St..4d ago
  • Benzinga's Top Upgrades, Downgrades For September 12, 2019
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
+0.95%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About INCY

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
More

Webull offers Incyte Corporation (INCY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.